SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending as the company reportedly began staking a portion of its significant Ethereum holdings, aiming to generate revenue. However, community discussions are dominated by strong concerns over consistent share dilution, the stock's perceived underperformance against Ethereum, and contentious executive compensation proposals. Many investors are also debating if current price weakness stems from year-end tax loss harvesting impacting digital asset treasury companies.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital (MARA) is generating significant discussion as it experiences new lows, fueling strong bearish sentiment centered on perceived share dilution and management's effectiveness. While many express frustration over its underperformance compared to Bitcoin and other miners, a bullish contingent believes the stock is deeply undervalued given its substantial Bitcoin holdings and a potential strategic pivot into AI/HPC data centers. The community remains sharply divided between those anticipating further declines and others predicting a major short squeeze and rebound, especially after year-end trading activities conclude.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending amidst a persistent downtrend that has frustrated many investors, fueling community discussion around market manipulation and the stock's daily declines. Despite this bearish sentiment, bulls highlight the company's international expansion, AI integration, and a share buyback program as strong long-term catalysts. The market is weighing Hims' direct-to-consumer model and GLP-1 strategy, particularly after the FDA approval of Novo Nordisk's oral weight-loss pill, creating a divide between those seeing a buying opportunity and those questioning its immediate prospects.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is seeing intense debate following a significant price decline, with market focus now squarely on potential announcements at the upcoming CES 2026. Bulls highlight strong fundamentals, growing revenue, and a substantial contractual backlog, seeing the current dip as a tax-loss selling opportunity amid perceived market manipulation. Conversely, bears are vocal about extensive insider selling and management's perceived lack of transparency regarding major partnerships, raising questions about the company's leadership and long-term prospects within the voice AI sector.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is gaining significant attention following a profitable asset sale that notably strengthened its balance sheet and sharpened its focus on core AI/edge compute. The community is actively discussing potential M&A opportunities and holds high anticipation for a substantial US Army contract where OSS is positioned as a sole-source provider. This enthusiasm is further fueled by recent strong earnings that exceeded expectations, with many viewing the company as an undervalued leader in the rapidly growing Edge AI sector.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA Acquisition Corp is actively trending amid speculation that it could be the next low-float SPAC to experience significant volatility, drawing comparisons to recent runners like AFJK and ASPC. The community is closely watching its recent extension of the business combination deadline and the proposed merger with The Original Fit Factory, with many debating its potential as a speculative "pump" play. This creates a divided sentiment between those anticipating a surge and others expressing skepticism about the merger's true intent and long-term value.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

BYTE is trending with strong community belief that it represents the future of AI, leveraging a narrative around potentially being Grok's digital companion. Enthusiasts are actively promoting the asset as 'the chosen one,' emphasizing the power of its dedicated community and urging others to 'byte the dip' in anticipation of significant developments. The sentiment suggests a conviction that this 'AI dog' is poised for a major impact in the crypto space.

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

TransCode Therapeutics Inc

TransCode Therapeutics (RNAZ) is trending following news of its acquisition of Polynoma and a significant strategic financing from CK Life Sciences, aimed at advancing its oncology pipeline. The community is actively discussing the associated Contingent Value Rights (CVR) distribution for existing shareholders, the company's low public float, and upcoming clinical data presentations at an industry conference, with many hoping for a significant market re-rating.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is trending after delivering a strong earnings report with robust revenue growth and a positive outlook for the crucial holiday shopping season, yet the stock saw an initial pullback, sparking active debate among investors. Community members are divided, with many advocating to "buy the dip" citing record merchant sales and strategic AI integrations, while others remain cautious, contributing to heightened volatility and discussions around its market valuation.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending amidst high anticipation for key regulatory decisions, particularly an upcoming FDA review for tradipitant and positive data on its application for GLP-1 induced nausea. The community is actively discussing the potential for these milestones to significantly re-rate the stock, emphasizing its strong financial position and an improved collaborative framework with regulators. Many perceive VNDA as currently undervalued, poised for substantial growth as its diverse pipeline targets significant market opportunities.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Inside the Recent Strength in Biotech ETFs 

Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.



2 ETFs to Watch for Outsized Volume on Biotechnology Stocks 

Biotech ETFs PBE and FBT saw trading volumes soar to over four times their averages, signaling rising interest amid a down day for major indexes.  

<ul class="summary-bullets"><li>Afrezza revenue rose 23% to $18.49 million in the three months through the end of September, owing to higher prices and demand.&nbsp;</li><li>Revenue from the V-Go insulin delivery patch, however, slipped 19% to $3.8 million due to low demand.&nbsp;</li><li>MannKind’s adjusted earnings per share came in at $0.07, above an analyst estimate of $0.02, according to data from Fiscal AI.&nbsp; &nbsp;</li></ul>Shares of MannKind Corporation (MNKD) rose 8% on Wednesday after the company reported 17% growth in total revenue to $82.13 million, thanks to significant growth in its Afrezza inhaled insulin sales.Afrezza revenue <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/05/3181424/29517/en/MannKind-Corporation-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html">rose</a> 23% to $18.49 million in the three months through the end of September, owing to higher prices and demand, while royalties rose to $33.32 million. Revenue from the V-Go insulin delivery patch, however, slipped 19% to $3.8 million due to low demand.<h2 class="st-heading-2">Q3 Performance</h2>MannKind’s adjusted earnings per share came in at $0.07, up from $0.06 in the corresponding quarter of 2024, and above an analyst estimate of $0.02, according to data from Fiscal AI.The company ended the quarter with cash, cash equivalents, and investments of $286.3 million, after utilizing approximately $133.2 million and borrowing an additional $250 million to fund the <a href="https://stocktwits.com/news-articles/markets/equity/mannkind-corporation-to-acquire-scpharmaceuticals/chssVp5Rd1m">acquisition</a> of scPharmaceuticals, which was completed in October.The acquisition is expected to accelerate MannKind’s revenue growth with the addition of Furoscix to its portfolio. Furoscix is used to treat fluid overload in adult patients with chronic heart failure (CHF) and chronic kidney disease (CKD).“The acquisition of scPharmaceuticals marks a significant expansion of our commercial capabilities and is expected to accelerate growth of our product revenues and build upon our commitment to delivering innovative, patient-centric therapies,” said Michael Castagna, CEO of MannKind.The company has now submitted a supplementary application to the FDA for approval of Afrezza in the pediatric population aged four to 17 years. The agency is expected to make a decision on the application by May 29, 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MNKD">MNKD stock</a> fell from ‘bullish’ to ‘bearish’ territory over the past 24 hours, while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:624/61;" src="data:image/png;base64,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" width="624" height="61" alt="MNKD's Sentiment Meter and Message Volume as of 11:00 a.m. ET on Nov. 5, 2025 | Source: Stocktwits"><figcaption>MNKD's Sentiment Meter and Message Volume as of 11:00 a.m. ET on Nov. 5, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that Wednesday’s gain in stock price might not last.<stembedurl>https://stocktwits.com/nomalarkey/message/635009498</stembedurl>Another sounded optimistic about the stock’s prospects.<stembedurl>https://stocktwits.com/6Figs/message/635008031</stembedurl>MNKD stock is down 8% this year and approximately 18% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-executives-including-cfo-rally-for-musk-s-one-trillion-pay-package/cL2qZJZREGA">Tesla Executives Including CFO Rally For Musk’s $1T Pay Package</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mannkind Corp and the company's inhalable insulin product. Company employee demonstrating how the device is used. (Photo by Lawrence K. Ho/Los Angeles Times via Getty Images)

MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters

The company has now also submitted a supplementary application to the FDA for approval of Afrezza in the pediatric population aged 4-17 years.

Equity

The company has now also submitted a supplementary application to the FDA for approval of Afrezza in the pediatric population aged 4-17 years.


<ul class="summary-bullets"><li>Vafseo is currently indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months.</li><li>The company said on Tuesday that it met with the U.S. Food and Drug Administration (FDA) but did not come to an agreement on a path forward for the design of a clinical trial in patients with late-stage chronic kidney disease not on dialysis.&nbsp;</li><li>Akebia believes regulatory alignment for such a trial would require a significantly larger number of patients than proposed. &nbsp;</li></ul>Shares of Akebia Therapeutics (AKBA) slumped 24% on Wednesday morning after the company said that it does not expect to pursue a broad label for Vafseo for the treatment of anemia in patients with late-stage chronic kidney disease not on dialysis.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.akebia.com/news-releases/news-release-details/akebia-therapeutics-provides-update-vafseo-non-dialysis-patients">said</a> on Tuesday that it met with the U.S. Food and Drug Administration (FDA) but did not come to an agreement on a path forward for the design of a clinical trial for the use of the drug in the said patient population.While the company is yet to receive the final minutes of the meeting with the FDA, Akebia believes regulatory alignment for such a trial would require a significantly larger number of patients than proposed. This, in turn, would require “meaningfully more” time and cost to complete, and the company does not plan to initiate the trial, the company said.<h2 class="st-heading-2">What Did The CEO Say?</h2>CEO John P. Butler said that the company is “disappointed” in the meeting outcome.“We believe our decision not to pursue a broad NDD-CKD label, based on our discussion with the FDA, is in the best interests of our shareholders. We were encouraged by the discussion with FDA on smaller subgroups of CKD patients where we may be able to align on a potential clinical trial design and path forward,” he added.Vafseo is currently indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months. In the second quarter ended June, the company reported Vafseo net product revenue of $13.3 million after nephrologists began prescribing it in January.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AKBA">AKBA stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user expressed optimism for the stock, saying the FDA did not shut the door on the trial in its entirety.<stembedurl>https://stocktwits.com/JonahTheTrader/message/634144578</stembedurl>Another highlighted that the company’s product is already on the market, and it has good financials.<stembedurl>https://stocktwits.com/Popeye989/message/634137009</stembedurl>AKBA stock is up by 23% this year and by 37% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/purple-biotech-shares-soar-on-breakthrough-for-experimental-cancer-drug/cLGZ8OAR3wS">Purple Biotech Shares Soar 92% On Breakthrough For Experimental Cancer Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Akebia Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion

Vafseo is currently indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months.

CEO John P. Butler said that the company is “disappointed” with the outcome of its meeting with the FDA on a path forward for the design of a clinical trial of Vafseo in patients with late-stage chronic kidney disease not on dialysis.

Several firms increased their price target on Ionis Pharmaceuticals (IONS) on Tuesday after the company announced positive results from a study of its Zilganersen drug in children and adults living with a rare neurological condition called Alexander disease (AxD).The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ionis.com/news-releases/news-release-details/ionis-announces-positive-topline-results-pivotal-study">announced</a> on Tuesday that in the study, Zilganersen 50 mg demonstrated statistically significant and clinically meaningful stabilization of the primary endpoint, gait speed, at week 61 compared to the control arm, with a favorable safety and tolerability profile. The company also said that Zilganersen indicated evidence of slowed disease progression, stabilization, or improvement.The firm intends to submit a new drug application to the U.S. Food and Drug Administration in the first quarter (Q1) of 2026. According to Ionis, Alexander Disease affects approximately one in one to three million people worldwide and has no approved disease-modifying treatments. The disease is characterized by progressive neurological deterioration, resulting in loss of functional mobility, independence, and the inability to control muscles for large movements, swallowing, and airway protection.Guggenheim on Tuesday raised its price target on the stock to $92 from $90, while maintaining a ‘Buy’ rating on the shares, according to TheFly. The new price target implies an upside of about 50% from the stock’s closing price on Monday.Other firms also hiked their price targets:<ol><li>Bank of America hiked its price target on IONS to $83 from $81 with a ‘Buy’ rating, while terming the news “an incremental positive” as Ionis could add another product to its expanding commercial portfolio.&nbsp;</li><li>Morgan Stanley hiked its price target on IONS to $86 from $71 while keeping an ‘Overweight’ rating on the shares.</li><li>Barclays also raised its price target on IONS to $80 from $78, with an ‘Overweight’ rating. The study results create a high probability of FDA approval, the analyst said.</li></ol>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IONS">IONS stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘low’ levels. Shares of the company traded over 2% higher at the time of writing.<figure class="image"><img style="aspect-ratio:574/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_23_at_11_39_52_AM_png_6ae39ea7d7.webp" alt="IONS' Sentiment Meter and Message Volume as of 11:40 a.m. ET on Sept. 23, 2025 | Source: Stocktwits" width="574" height="63"><figcaption>IONS' Sentiment Meter and Message Volume as of 11:40 a.m. ET on Sept. 23, 2025 | Source: Stocktwits</figcaption></figure>IONS' stock is up 80% this year and approximately 50% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-regulator-closes-probe-into-ford-bronco-vehicles-after-recent-recall/chDhCRLR35q">US Regulator Closes Probe Into Ford Bronco Vehicles – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ionis Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease

Guggenheim on Tuesday hiked the price target on the stock to $92 from $90 while keeping a ‘Buy’ rating on the shares. 

PBE
Invesco Dynamic Biotechnology & Genome ETF

Feed

News

Sentiment

Fundamentals

Info

Latest PBE News

PBEInvesco Dynamic Biotechnology & Genome ETF